SAP SE

  • WKN: 716460
  • ISIN: DE0007164600
  • Land: Deutschland

Nachricht vom 12.12.2011 | 15:27

SAP AG: Release according to Article 30e of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


SAP AG  / Third country release according to Article 30e Para. 1, No. 3
of the WpHG [the German Securities Trading Act]

12.12.2011 15:27

Dissemination of a Post-admission Duties announcement according to Article
30e Para. 1 No. 3 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

With ad hoc announcement dated December 3, 2011 SAP AG ('SAP') announced that SAP's subsidiary, SAP America, Inc., has entered into a definitive merger agreement with SuccessFactors, Inc. ('SuccessFactors') pursuant to which a subsidiary of SAP would offer to acquire all outstanding shares of common stock of SuccessFactors. In connection with this merger agreement, SAP has filed on December 9, 2011 with the U.S. Securities and Exchange Commission (SEC) the following documents: A Schedule TO-C including - 'Exhibit (a)(5)(O) - Transcript of Barclays Capital Global Technology Conference held on December 8, 2011' These documents are available on the website of SAP AG under http://www.sap.com/corporate-en/investors/successfactors/offer.epx. 12.12.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: SAP AG Dietmar-Hopp-Allee 16 69190 Walldorf Germany Internet: www.sap.com End of Announcement DGAP News-Service

GBC im Fokus

Neovacs S.A.: Kurzfristige Potenziale durch Fast-Track-Zulassung möglich

Das in Frankreich ansässige Biotechnologieunternehmen Neovacs S.A. fokussiert sich auf die Entwicklung so genannter Kinoide, welche für die Behandlung von Autoimmunerkrankungen sowie entzündlichen Erkrankungen verwendet werden. Der Neovacs-Wirkstoff wird derzeit im Rahmen einer klinischen Studie IIb (SLE) in 19 Ländern (Europa, Asien, Lateinamerika, USA) an 178 Patienten untersucht. Wir rechnen mit den ersten Ergebnissen in Sommer 2017. Im Rahmen des DCF-Bewertungsmodells haben wir inkl. eines hohen Sicherheitsabschlages einen fairen Wert von2,90 € je Aktie ermittelt. Wir vergeben das Rating KAUFEN.

Aktueller Webcast

EQS Group AG

Conference Call - 6-Monatsbericht 2016

26. August 2016

Aktuelle Research-Studie

Uzin Utz AG

Original-Research: Uzin Utz AG (von Montega AG): Halten

25. August 2016